CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 84% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
Country • United States
    Entity • The products and services listed on this website are not available to US residents.
    English العَرَبِيَّة Bahasa Indonesia Български Čeština Dansk Deutsch Eesti ελληνικά Español Français Hrvatski Italiano Latviešu Lietuvių Magyar Nederlands Polski Português Română Русский Slovenčina Slovenščina Suomi Svenska Tiếng Việt ไทย 简体中文 繁體中文

    Trade Idera Pharma - IDRA CFD

    0.40
    24.53%
    • Summary
    • Historical Data
    • Events
    • Income Statement
    • Balance Sheet
    • Cash Flow
    • Ownership
    Trading Conditions
    Spread 0.05
    Long position overnight fee

    Long position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee -0.025457 %
    Charges from borrowed part ($-1.02)
    Trade size with leverage ~ $5,000.00
    Money from leverage ~ $4,000.00
    Go to platform
    		-0.025457%
    Short position overnight fee

    Short position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee 0.003235 %
    Charges from borrowed part ($0.13)
    Trade size with leverage ~ $5,000.00
    Money from leverage ~ $4,000.00
    Go to platform
    		0.003235%
    Overnight fee time 21:00 (UTC)
    Min traded quantity 1
    Currency USD
    Margin 20%
    Stock exchange United States of America
    Commission on trade 0%

    *Information provided by Capital.com

    Aceragen Inc ESG Risk Ratings

    High Medium Low Negligible

    ‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.

    More ESG coverage

    Key Stats
    Prev. Close* 0.53
    Open* 0.46
    1-Year Change* -28.13%
    Day's Range* 0.4 - 0.46
    52 wk Range 0.30-0.95
    Average Volume (10 days) 76.59K
    Average Volume (3 months) 2.20M
    Market Cap 21.41M
    P/E Ratio -100.00K
    Shares Outstanding 62.36M
    Revenue N/A
    EPS -0.34
    Dividend (Yield %) N/A
    Beta 1.43
    Next Earnings Date Mar 29, 2023

    All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

    • Last Week
    • Last Month
    • Last Year
    • Last two Years
    • Max
    • Daily
    • Weekly
    • Monthly
    Date Close Change Change (%) Open High Low
    Jan 17, 2023 0.40 -0.06 -13.04% 0.46 0.47 0.40
    Jan 13, 2023 0.53 0.00 0.00% 0.53 0.53 0.52
    Jan 12, 2023 0.53 0.02 3.92% 0.51 0.54 0.50
    Jan 11, 2023 0.48 0.04 9.09% 0.44 0.49 0.41
    Jan 10, 2023 0.44 -0.17 -27.87% 0.61 0.64 0.41
    Jan 9, 2023 0.64 -0.04 -5.88% 0.68 0.68 0.63
    Jan 6, 2023 0.66 0.03 4.76% 0.63 0.69 0.63
    Jan 5, 2023 0.63 0.12 23.53% 0.51 0.65 0.51
    Jan 4, 2023 0.53 0.10 23.26% 0.43 0.53 0.43
    Jan 3, 2023 0.43 0.03 7.50% 0.40 0.45 0.39
    Nov 15, 2022 0.38 -0.02 -5.00% 0.40 0.40 0.38
    Nov 11, 2022 0.38 0.00 0.00% 0.38 0.38 0.38
    Nov 10, 2022 0.38 0.00 0.00% 0.38 0.38 0.38
    Nov 8, 2022 0.39 -0.02 -4.88% 0.41 0.41 0.39
    Nov 7, 2022 0.40 0.00 0.00% 0.40 0.41 0.39
    Nov 4, 2022 0.39 -0.01 -2.50% 0.40 0.40 0.39
    Nov 3, 2022 0.41 0.00 0.00% 0.41 0.42 0.39
    Nov 2, 2022 0.39 -0.05 -11.36% 0.44 0.45 0.39
    Nov 1, 2022 0.45 0.04 9.76% 0.41 0.46 0.40
    Oct 31, 2022 0.41 0.03 7.89% 0.38 0.44 0.38

    Idera Pharma Events

    Time (UTC) Country Event
    Thursday, June 8, 2023

    Time (UTC)

    20:15

    Country

    US

    Event

    Q1 2023 Idera Pharmaceuticals Inc Earnings Release
    Q1 2023 Idera Pharmaceuticals Inc Earnings Release

    Forecast

    -

    Previous

    -
    Monday, August 7, 2023

    Time (UTC)

    10:59

    Country

    US

    Event

    Q2 2023 Idera Pharmaceuticals Inc Earnings Release
    Q2 2023 Idera Pharmaceuticals Inc Earnings Release

    Forecast

    -

    Previous

    -
    Monday, November 13, 2023

    Time (UTC)

    10:59

    Country

    US

    Event

    Q3 2023 Idera Pharmaceuticals Inc Earnings Release
    Q3 2023 Idera Pharmaceuticals Inc Earnings Release

    Forecast

    -

    Previous

    -
    View all events
    • Annual
    • Quarterly
    2021 2020 2019 2018 2017
    Total revenue 0 0 1.448 0.662 0.902
    Revenue 0 0 1.448 0.662 0.902
    Total Operating Expense 27.673 36.687 47.515 61.618 67.369
    Selling/General/Admin. Expenses, Total 9.976 11.915 12.481 15.42 16.716
    Research & Development 16.375 24.772 34.853 41.841 50.653
    Operating Income -27.673 -36.687 -46.067 -60.956 -66.467
    Interest Income (Expense), Net Non-Operating 6.961 0.134 0.516 1.075 0.483
    Net Income Before Taxes 98.091 -112.662 -56.515 -59.881 -65.984
    Net Income After Taxes 98.091 -112.662 -56.515 -59.881 -65.984
    Net Income Before Extra. Items 98.091 -112.662 -56.515 -59.881 -65.984
    Net Income 98.091 -112.662 -56.515 -59.881 -65.984
    Total Adjustments to Net Income -1.15 0 -28.043
    Income Available to Common Excl. Extra. Items 96.941 -112.662 -84.558 -59.881 -65.984
    Income Available to Common Incl. Extra. Items 96.941 -112.662 -84.558 -59.881 -65.984
    Diluted Net Income 96.941 -112.662 -84.558 -59.881 -65.984
    Diluted Weighted Average Shares 50.127 33.821 28.545 26.601 19.6747
    Diluted EPS Excluding Extraordinary Items 1.93391 -3.33113 -2.96227 -2.25108 -3.35374
    Diluted Normalized EPS 1.96028 -3.33113 -2.95593 -2.08729 -3.35374
    Total Extraordinary Items 0
    Unusual Expense (Income) 1.322 0 0.181 4.357
    Other, Net 118.803 -76.109 -10.964
    Mar 2022 Dec 2021 Sep 2021 Jun 2021 Mar 2021
    Total revenue 0 0 0 0 0
    Total Operating Expense 4.182 4.121 5.968 7.557 10.027
    Selling/General/Admin. Expenses, Total 2.398 2.017 2.331 2.472 3.156
    Research & Development 1.784 2.104 3.507 3.893 6.871
    Operating Income -4.182 -4.121 -5.968 -7.557 -10.027
    Interest Income (Expense), Net Non-Operating 0.004 0.002 0.003 -0.006 6.962
    Other, Net 0 0 0 118.803
    Net Income Before Taxes -4.178 -4.119 -5.965 -7.563 115.738
    Net Income After Taxes -4.178 -4.119 -5.965 -7.563 115.738
    Net Income Before Extra. Items -4.178 -4.119 -5.965 -7.563 115.738
    Net Income -4.178 -4.119 -5.965 -7.563 115.738
    Income Available to Common Excl. Extra. Items -4.178 -5.269 -5.965 -7.563 115.738
    Income Available to Common Incl. Extra. Items -4.178 -5.269 -5.965 -7.563 115.738
    Diluted Net Income -4.178 -5.269 -5.965 -7.563 115.738
    Diluted Weighted Average Shares 52.893 52.842 52.74 49.909 70.98
    Diluted EPS Excluding Extraordinary Items -0.07899 -0.09971 -0.1131 -0.15154 1.63057
    Dividends per Share - Common Stock Primary Issue 0 0 0 0
    Diluted Normalized EPS -0.07899 -0.09971 -0.11064 -0.12765 1.63057
    Unusual Expense (Income) 0 0.13 1.192
    Revenue 0
    Total Adjustments to Net Income 0 -1.15
    Dilution Adjustment 0
    • Annual
    • Quarterly
    2021 2020 2019 2018 2017
    Total Current Assets 34.038 41.355 46.268 72.807 116.621
    Cash and Short Term Investments 32.545 37.728 42.793 71.431 112.629
    Cash & Equivalents 32.545 33.229 40.019 71.431 112.629
    Short Term Investments 0 4.499 2.774 0
    Prepaid Expenses 1.493 3.627 3.475 1.376 3.992
    Total Assets 34.864 42.399 47.489 73.023 118.417
    Property/Plant/Equipment, Total - Net 0.756 0.974 1.151 0.207 1.472
    Property/Plant/Equipment, Total - Gross 1.553 1.807 1.925 0.871 5.932
    Accumulated Depreciation, Total -0.797 -0.833 -0.774 -0.664 -4.46
    Long Term Investments
    Other Long Term Assets, Total 0.07 0.07 0.07 0.009 0.324
    Total Current Liabilities 4.862 7.027 54.517 9.018 10.109
    Accounts Payable 0.565 0.329 0.457 1.134 1.334
    Accrued Expenses 4.297 6.263 7.624 7.884 8
    Notes Payable/Short Term Debt 0 0 0 0 0
    Current Port. of LT Debt/Capital Leases 0 0 0 0.209
    Other Current Liabilities, Total 0 0.435 46.436 0 0.566
    Total Liabilities 5.411 133.571 58.657 9.029 10.722
    Total Long Term Debt 0 0 0 0 0
    Long Term Debt 0
    Other Liabilities, Total 0.549 126.544 4.14 0.011 0.613
    Total Equity 29.453 -91.172 -11.168 63.994 107.695
    Preferred Stock - Non Redeemable, Net 0 0 0
    Common Stock 0.053 0.038 0.03 0.027 0.196
    Additional Paid-In Capital 764.861 742.342 709.692 728.342 711.993
    Retained Earnings (Accumulated Deficit) -735.461 -833.552 -720.89 -664.375 -604.494
    Other Equity, Total 0
    Total Liabilities & Shareholders’ Equity 34.864 42.399 47.489 73.023 118.417
    Total Common Shares Outstanding 52.818 38.291 29.672 27.188 24.4531
    Total Preferred Shares Outstanding 0.001 0.025 0.025 0.001 0.001
    Redeemable Preferred Stock 0
    Mar 2022 Dec 2021 Sep 2021 Jun 2021 Mar 2021
    Total Current Assets 29.362 34.038 38.299 43.475 47.018
    Cash and Short Term Investments 27.993 32.545 36.602 40.59 44.541
    Cash & Equivalents 27.993 32.545 36.602 40.59 44.541
    Short Term Investments 0 0 0
    Prepaid Expenses 1.369 1.493 1.697 2.885 2.477
    Total Assets 30.133 34.864 39.18 44.411 48.008
    Property/Plant/Equipment, Total - Net 0.701 0.756 0.811 0.866 0.92
    Property/Plant/Equipment, Total - Gross 1.502 1.553 1.603 1.652 1.716
    Accumulated Depreciation, Total -0.801 -0.797 -0.792 -0.786 -0.796
    Other Long Term Assets, Total 0.07 0.07 0.07 0.07 0.07
    Total Current Liabilities 3.796 4.862 5.566 6.029 4.996
    Accounts Payable 0.24 0.565 0.276 0.184 0.185
    Accrued Expenses 3.556 4.297 5.29 5.845 4.594
    Notes Payable/Short Term Debt 0 0 0 0 0
    Current Port. of LT Debt/Capital Leases 0 0 0 0 0
    Other Current Liabilities, Total 0 0 0 0.217
    Total Liabilities 4.29 5.411 6.169 6.685 5.704
    Total Long Term Debt 0 0 0 0 0
    Other Liabilities, Total 0.494 0.549 0.603 0.656 0.708
    Total Equity 25.843 29.453 33.011 37.726 42.304
    Preferred Stock - Non Redeemable, Net 0 0 0
    Common Stock 0.053 0.053 0.053 0.052 0.046
    Additional Paid-In Capital 765.429 764.861 764.3 763.051 760.072
    Retained Earnings (Accumulated Deficit) -739.639 -735.461 -731.342 -725.377 -717.814
    Total Liabilities & Shareholders’ Equity 30.133 34.864 39.18 44.411 48.008
    Total Common Shares Outstanding 52.924 52.818 52.777 52.115 46.537
    Total Preferred Shares Outstanding 0.001 0.001 0.001 0.001 0.011
    • Annual
    • Quarterly
    2021 2020 2019 2018 2017
    Net income/Starting Line 98.091 -112.662 -56.515 -59.881 -65.984
    Cash From Operating Activities -24.597 -33.772 -44.498 -51.916 -55.259
    Cash From Operating Activities 0.022 0.061 0.12 0.432 0.746
    Non-Cash Items -123.098 79.947 15.154 6.248 10.964
    Cash Interest Paid 0.005 0 0 0.009 0.042
    Changes in Working Capital 0.388 -1.118 -3.257 1.285 -0.985
    Cash From Investing Activities 4.5 -1.687 -2.402 0.215 28.064
    Capital Expenditures 0 -0.008 -0.011 -0.075 -0.206
    Other Investing Cash Flow Items, Total 4.5 -1.679 -2.391 0.29 28.27
    Cash From Financing Activities 19.413 28.669 15.488 10.192 59.157
    Issuance (Retirement) of Stock, Net 19.848 28.886 5.422 10.409 59.46
    Issuance (Retirement) of Debt, Net -0.435 -0.217 -0.006 -0.217 -0.303
    Net Change in Cash -0.684 -6.79 -31.412 -41.509 31.962
    Financing Cash Flow Items 0 10.072
    Mar 2022 Dec 2021 Sep 2021 Jun 2021 Mar 2021
    Net income/Starting Line -4.178 98.091 102.21 108.175 115.738
    Cash From Operating Activities -4.568 -24.597 -20.545 -15.85 -9.591
    Cash From Operating Activities 0.004 0.022 0.017 0.011 0.006
    Non-Cash Items 0.567 -123.098 -123.667 -124.142 -124.609
    Cash Interest Paid 0 0.005 0.005 0.005 0.003
    Changes in Working Capital -0.961 0.388 0.895 0.106 -0.726
    Cash From Investing Activities 0 4.5 4.5 4.5 4.5
    Capital Expenditures 0 0 0
    Other Investing Cash Flow Items, Total 0 4.5 4.5 4.5 4.5
    Cash From Financing Activities 0.016 19.413 19.418 18.711 16.403
    Issuance (Retirement) of Stock, Net 0.016 19.848 19.853 19.146 16.621
    Issuance (Retirement) of Debt, Net 0 -0.435 -0.435 -0.435 -0.218
    Net Change in Cash -4.552 -0.684 3.373 7.361 11.312
    Financing Cash Flow Items 0

    Start a global, multi-asset portfolio with an award-winning platform

    Desktop

    Trading calculator

    Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

    Trade commission
    0
    • 1:1
    Leverage
    1:1
    • 20
    • 100
    • 500
    • 1000
    • 10000
    Investment
    Trade size (Leverage x Investement):
    Open

    Close

    Short Long
    Past performance is not a reliable indicator of future results
    Profit/Loss

    Idera Pharma Company profile

    About Idera Pharmaceuticals Inc

    Idera Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on clinical development and commercialization of drug candidates for both oncology and rare disease. The Company is engaged on Toll-like receptor (TLR) agonist, tilsotolimod (IMO-2125), for oncology. It uses its chemistry-based platform to design both TLR agonists and antagonists to act by modulating the activity of targeted TLRs. Its TLR-targeted clinical-stage drug candidate, tilsotolimod, is an agonist of TLR9. The Company is developing tilsotolimod, via intratumoral injection in combination with inhibitors and costimulation therapies for the treatment of various solid tumors, including anti-programmed-death-receptor-1 (anti-PD1) refractory metastatic melanoma, microsatellite stable (MSS) colorectal cancer (CRC) and squamous cell carcinoma of the head and neck (HNSCC). It refers tilsotolimod development program as the ILLUMINATE development program.

    Financial summary

    BRIEF: For the nine months ended 30 September 2021, Idera Pharmaceuticals Inc revenues was not reported. Net income totaled $102.2M vs. loss of $36M. Net income reflects Future tranche right revaluation gain increase from $7M (expense) to $118.8M (income), Warrant revaluation gain increase from $188K to $7M (income), Research and development - Balancing decrease of 28% to $13.8M (expense).

    Equity composition

    Common Stock $.001 Par, 02/12, 70M auth., 27,637,007 issd., Insiders control 15.21%. IPO:2/96, 5,750,000 shs. @ $10 by Lehman Brothers. 12/97, 1-for-5 reverse split. FY'00 Q's are RES. 8/03 20,053,022 shs. issd. in a private placement. 9/05, 12/07, Company delisted from AMEX to NASDAQ.

    Industry: Biotechnology & Medical Research (NEC)

    505 Eagleview Boulevard
    Suite 212
    EXTON
    PENNSYLVANIA 19341
    US

    Income Statement

    • Annual
    • Quarterly

    News

    Turkish lira on top of USA national currency, top view of mixed American dollars banknotes. TRY and USA paper money. Lira and US dollars exchange rate

    USD/TRY forecast: Turkish lira under pressure from high inflation and low rates

    We look at some of the latest USD/TRY predictions as the Turkish lira hits record lows.

    17:07, 1 June 2023
    Nvidia HQ in Santa Clara, California

    Nvidia’s 5-year stock forecast: Will the chipmaker remain at record highs?

    Nvidia has been the winner of the AI race, being the first chip-maker to hit a $1tn market cap. Will the growth continue?

    07:46, 31 May 2023
    Alphabet Inc and Google logos on a smartphone screen

    Google stock forecast 2023-2025

    What is the outlook for the tech giant, following a tumultuous 2022?

    18:02, 30 May 2023
    Benjamin Franklin’s face on a $100 bill

    USD forecast: DXY slides in risk-off market sentiment

    The DXY hit a seven-month low in January, just a few months after a multi-decade peak in late September.

    16:10, 24 May 2023
    Oil wells pictured in an oil field, silhouetted against clouds

    Oil price forecast: Will WTI and Brent regain momentum in 2023?

    Discover the drivers behind Brent and WTI volatility and get insights from analyst predictions.

    11:38, 22 May 2023
    businessman using a mobile phone to check stock market data

    Weekly Roundup: Tech stocks lead the way

    US stocks push higher as risk appetite surges despite the uncertainty

    13:39, 19 May 2023
    Japanese yen currency

    USD/JPY continues to build higher towards 138

    USD/JPY advances towards the top of its ascending triangle as the US dollar moves higher

    11:50, 17 May 2023

    People also watch

    BTC/USD

    26,428.50 Price
    +0.120% 1D Chg, %
    Long position overnight fee -0.0616%
    Short position overnight fee 0.0137%
    Overnight fee time 21:00 (UTC)
    Spread 60.00

    US100

    14,322.20 Price
    +0.190% 1D Chg, %
    Long position overnight fee -0.0255%
    Short position overnight fee 0.0032%
    Overnight fee time 21:00 (UTC)
    Spread 1.8

    Oil - Crude

    73.16 Price
    +0.840% 1D Chg, %
    Long position overnight fee -0.0156%
    Short position overnight fee -0.0063%
    Overnight fee time 21:00 (UTC)
    Spread 0.03

    Gold

    1,947.25 Price
    +0.370% 1D Chg, %
    Long position overnight fee -0.0090%
    Short position overnight fee 0.0008%
    Overnight fee time 21:00 (UTC)
    Spread 0.30

    Still looking for a broker you can trust?

    Join the 535.000+ traders worldwide that chose to trade with Capital.com

    1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading